Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers

Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad V. Pecot, Yan Sun, Lingegowda S. Mangala, Xia Li, Ping Ji, David Cogdell, Limei Hu, Yingmei Wang, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Ilya Shmulevich, Loris De Cecco, Kexin Chen, Delia Mezzanzanica, Fengxia Xue, Anil K. Sood, Wei Zhang

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers. Methods: We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided. Results: MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.90 to 4.70, P

Original languageEnglish (US)
Article numberdjv108
JournalJournal of the National Cancer Institute
Volume107
Issue number7
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

MicroRNAs
Ovarian Neoplasms
Disease-Free Survival
Drug Therapy
Epithelial-Mesenchymal Transition
Atlases
Homologous Recombination
Cisplatin
Neoplasms
Genome
Confidence Intervals
Therapeutics
Ovarian epithelial cancer
Poly(ADP-ribose) Polymerase Inhibitors
Datasets
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. / Liu, Guoyan; Yang, Da; Rupaimoole, Rajesha; Pecot, Chad V.; Sun, Yan; Mangala, Lingegowda S.; Li, Xia; Ji, Ping; Cogdell, David; Hu, Limei; Wang, Yingmei; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Shmulevich, Ilya; De Cecco, Loris; Chen, Kexin; Mezzanzanica, Delia; Xue, Fengxia; Sood, Anil K.; Zhang, Wei.

In: Journal of the National Cancer Institute, Vol. 107, No. 7, djv108, 01.07.2015.

Research output: Contribution to journalArticle

Liu, G, Yang, D, Rupaimoole, R, Pecot, CV, Sun, Y, Mangala, LS, Li, X, Ji, P, Cogdell, D, Hu, L, Wang, Y, Rodriguez-Aguayo, C, Lopez-Berestein, G, Shmulevich, I, De Cecco, L, Chen, K, Mezzanzanica, D, Xue, F, Sood, AK & Zhang, W 2015, 'Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers', Journal of the National Cancer Institute, vol. 107, no. 7, djv108. https://doi.org/10.1093/jnci/djv108
Liu, Guoyan ; Yang, Da ; Rupaimoole, Rajesha ; Pecot, Chad V. ; Sun, Yan ; Mangala, Lingegowda S. ; Li, Xia ; Ji, Ping ; Cogdell, David ; Hu, Limei ; Wang, Yingmei ; Rodriguez-Aguayo, Cristian ; Lopez-Berestein, Gabriel ; Shmulevich, Ilya ; De Cecco, Loris ; Chen, Kexin ; Mezzanzanica, Delia ; Xue, Fengxia ; Sood, Anil K. ; Zhang, Wei. / Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. In: Journal of the National Cancer Institute. 2015 ; Vol. 107, No. 7.
@article{2e31a0bebcf74f20ae44b5b58a8bf9b1,
title = "Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers",
abstract = "Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers. Methods: We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided. Results: MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95{\%} confidence interval [CI] = 1.90 to 4.70, P",
author = "Guoyan Liu and Da Yang and Rajesha Rupaimoole and Pecot, {Chad V.} and Yan Sun and Mangala, {Lingegowda S.} and Xia Li and Ping Ji and David Cogdell and Limei Hu and Yingmei Wang and Cristian Rodriguez-Aguayo and Gabriel Lopez-Berestein and Ilya Shmulevich and {De Cecco}, Loris and Kexin Chen and Delia Mezzanzanica and Fengxia Xue and Sood, {Anil K.} and Wei Zhang",
year = "2015",
month = "7",
day = "1",
doi = "10.1093/jnci/djv108",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers

AU - Liu, Guoyan

AU - Yang, Da

AU - Rupaimoole, Rajesha

AU - Pecot, Chad V.

AU - Sun, Yan

AU - Mangala, Lingegowda S.

AU - Li, Xia

AU - Ji, Ping

AU - Cogdell, David

AU - Hu, Limei

AU - Wang, Yingmei

AU - Rodriguez-Aguayo, Cristian

AU - Lopez-Berestein, Gabriel

AU - Shmulevich, Ilya

AU - De Cecco, Loris

AU - Chen, Kexin

AU - Mezzanzanica, Delia

AU - Xue, Fengxia

AU - Sood, Anil K.

AU - Zhang, Wei

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers. Methods: We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided. Results: MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.90 to 4.70, P

AB - Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers. Methods: We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided. Results: MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.90 to 4.70, P

UR - http://www.scopus.com/inward/record.url?scp=84939500019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939500019&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv108

DO - 10.1093/jnci/djv108

M3 - Article

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

M1 - djv108

ER -